Serena H. Chen, MD, Joins the Theralogix Medical Advisory Board

Serena H. Chen, MD, Joins the Theralogix Medical Advisory Board

Dr. Chen’s expertise and notable achievements help reinforce the company’s commitment to science and evidence-backed supplements.

Theralogix, a national leader in the supplement industry, announces the addition of Serena H. Chen, MD, to its esteemed Medical Advisory Board. Dr. Chen’s numerous credentials and extensive experience in the field of reproductive medicine make her a valuable asset to the board. 

Serena H. Chen, MD, graduated from Brown University and earned her MD at Duke University School of Medicine. She trained in Gynecology, Obstetrics, Reproductive Endocrinology & Infertility at The Johns Hopkins Hospital and now holds multiple distinguished titles including Director for the Division of Reproductive Medicine at Cooperman Barnabas Medical Center, Chief Advocacy Officer at CCRM NJ, and a Founder and Vice President of Doctors for Fertility NFP.

Dr. Chen strongly supports her patients’ right to be informed and involved in their own care, and she is passionate about access to fertility treatment for all. In 2020, Dr. Chen was the recipient of Resolve’s prestigious Hope Award, recognizing her advocacy for legislation that ensures access to care for those diagnosed with infertility. 

Theralogix was founded on science and the commitment that every product has extensive research to back it up. Theralogix’s Medical Advisory Board (MAB) plays a vital role in solidifying this dedication to science-backed products. Made up of a carefully selected group of physicians, top research scientists, and faculty members at leading U.S. medical schools, the MAB evaluates and approves new product formulations, while offering guidance to improve existing ones.  

Theralogix sets the standard for premium, research-backed nutritional supplements. Each product in their full line of supplements is independently certified by NSF® International for content accuracy and freedom from contaminants. Theralogix has been a top physician-recommended brand for over two decades. For more information about Theralogix and its range of evidence-based products, please visit the Theralogix website.

Contact Information:

Shannon Mahon

[email protected]

301.464.7210

Original Source:

Serena H. Chen, MD, Joins the Theralogix Medical Advisory Board

The post Serena H. Chen, MD, Joins the Theralogix Medical Advisory Board first appeared on Enrose Magazine.

Continue Reading

Get Well Achieves FedRAMP Authorized Designation

Get Well Achieves FedRAMP Authorized Designation

Company’s Cross-Continuum Digital Patient Engagement Platform Will Enable Federal Organizations to Securely Personalize Patient Outreach Across a Full Episode of Care

Get Well Achieves FedRAMP Authorized Designation
Get Well provides enterprise digital patient experience and navigation solutions for hospitals and communities around the world.

Get Well, the global leader in digital patient engagement, today announced that it has achieved Federal Risk and Authorization Management Program (FedRAMP) authority to operate (ATO) at the Moderate security impact level for its cross-continuum digital patient engagement platform.

Get Well delivers a cross-continuum digital patient engagement platform for every step of the care journey, both inside and outside the hospital. Hosted on the AWS GovCloud, the Get Well platform provides a seamless experience for every Veteran and active-duty military member and their families, personalized to their healthcare needs and reaching them across a full episode of care, as well as in between episodes. Get Well’s platform enables longitudinal engagement and activation to bring patients back in network for new episodes, including personalized outreach at scale leveraging AI-powered text and services, and offers seamless integration into Cerner, Epic and other EHRs. 

Now listed on the FedRAMP Marketplace, the Get Well digital patient engagement platform can be contracted by any government agency without additional security vetting required — eliminating onboarding costs and accelerating time to implementation. 

FedRAMP is a government-wide program that promotes the adoption of secure cloud services across the federal government by providing a standardized approach to security assessment, authorization, and continuous monitoring for cloud products and services. FedRAMP empowers agencies to use modern cloud technologies, with an emphasis on security and protection of federal information.

“Get Well has been honored to serve the Veterans Health Administration and Defense Health Agency for the past 12 years. Obtaining FedRAMP certification affirms our belief that a cross-continuum platform approach, leveraging high tech and high touch, is required to help navigate members of our military communities to the best care possible,” said Michael O’Neil, founder and CEO, Get Well. “We believe that the FedRAMP ATO, along with our current integrations with VistA/CPRS and our partnership with Oracle Cerner, positions us now and well into the future to be an even better engagement solution for Veteran and Military patients.”

Today, Get Well serves 70+ Veteran Affairs Medical Centers (VAMCs) representing over 13,000 patient beds. The company’s high-tech and high-touch digital patient engagement solutions have driven a 45% improvement in patient experience scores, a 31% decrease in hospital-acquired infection rates and a 14% decrease in average length of stay for federal hospitals around the country. 

About Get Well

Get Well provides enterprise digital patient experience and navigation solutions for hospitals and communities around the world. Our products empower healthcare organizations to deliver patient-centered experiences that drive retention and growth, increase patient satisfaction, improve clinical quality and reduce cost of care. Learn more at getwellnetwork.com or follow Get Well on LinkedIn and Twitter

Contact Information:

Adrienne Chen

[email protected]

(415) 722-1907

Original Source:

Get Well Achieves FedRAMP Authorized Designation

The post Get Well Achieves FedRAMP Authorized Designation first appeared on Enrose Magazine.

Continue Reading

Ischemix, Inc. Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI); Preparing for Conduct of Phase 2 Trial

Ischemix, Inc. Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI); Preparing for Conduct of Phase 2 Trial

CMX-2043, a novel, proprietary cytoprotective drug candidate, demonstrated excellent safety and tolerability in a Phase 1 single ascending and multiple ascending dose (SAD-MAD) clinical trial. CMX-2043 has previously d…

The post Ischemix, Inc. Completes Successful Phase 1 Trial of Novel Compound to Treat Traumatic Brain Injury (TBI); Preparing for Conduct of Phase 2 Trial first appeared on Enrose Magazine.

Continue Reading

Radical Imaging Joins NVIDIA Inception

Radical Imaging Joins NVIDIA Inception

Joining Program Will Help Accelerate AI Capabilities in FlexView, Radical Imaging’s Viewer-as-a-Service Product

Radical Imaging Joins NVIDIA Inception
FlexView

FlexView

Radical Imaging LLC, a pioneer in medical imaging informatics, interoperability, and integrations, announced today that it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.

Radical Imaging’s new product, FlexView, is a professionally supported, SaaS cloud-native medical imaging viewer based on the Open Health Imaging Foundation (OHIF) framework. It is a commercial-grade, production-ready solution that can easily be incorporated into any medical imaging system, seamlessly providing viewing and analysis capabilities for any type of medical image or workflow. FlexView adds to OHIF’s extensibility model by introducing the ability to deploy plug-ins at runtime. This is crucial to enable the addition of new features dynamically, such as AI-based tools, without causing disruptions or system downtime.

Joining NVIDIA Inception will help Radical Imaging accelerate FlexView’s integration with MONAI in order to unlock AI capabilities in FlexView. The program will also offer Radical Imaging the opportunity to collaborate with industry-leading experts and other AI-driven organizations.

“We’re excited to join the list of startups in NVIDIA Inception, and we’re grateful to work with NVIDIA. Considering how fast-moving AI is right now, this program gives us confidence that our viewing solution will be able to leverage the advances in AI, even as the field continues to evolve,” said Rob Lewis, CEO of Radical Imaging. 

NVIDIA Inception helps startups during critical stages of product development, prototyping, and deployment. Every NVIDIA Inception member gets a custom set of ongoing benefits, such as NVIDIA Deep Learning Institute credits, preferred pricing on NVIDIA hardware and software, and technological assistance, which provides startups with the fundamental tools to help them grow.

About Radical Imaging LLC

Radical Imaging is a software company focused entirely on medical imaging. It offers software system design and planning, contract software development, and consulting to help its partners solve their most challenging medical imaging problems using modern cloud and web platforms like Cornerstone.js and OHIF, which it co-developed with Massachusetts General Hospital. In 2023, Radical Imaging will be releasing its first commercial product, FlexView, a commercial version of OHIF. For more information, visit RadicalImaging.com.

Contact Information:

Radical Imaging

[email protected]

Original Source:

Radical Imaging Joins NVIDIA Inception

The post Radical Imaging Joins NVIDIA Inception first appeared on Enrose Magazine.

Continue Reading